News coverage about Forward Pharma A/S (NASDAQ:FWP) has trended positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Forward Pharma A/S earned a news sentiment score of 0.27 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 44.7698655481342 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Shares of Forward Pharma A/S (NASDAQ:FWP) opened at 24.40 on Friday. Forward Pharma A/S has a 1-year low of $14.89 and a 1-year high of $33.00.

A number of research firms have recently commented on FWP. ValuEngine raised Forward Pharma A/S from a “sell” rating to a “hold” rating in a report on Saturday, June 17th. BidaskClub raised Forward Pharma A/S from a “sell” rating to a “hold” rating in a research note on Tuesday, June 20th. Finally, Jefferies Group LLC set a $22.00 price objective on Forward Pharma A/S and gave the company a “hold” rating in a research note on Tuesday, April 18th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Forward Pharma A/S has an average rating of “Buy” and an average price target of $24.00.

TRADEMARK VIOLATION WARNING: This story was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.dailypolitical.com/2017/08/13/positive-news-coverage-somewhat-unlikely-to-impact-forward-pharma-as-nasdaqfwp-stock-price.html.

About Forward Pharma A/S

Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis.

Insider Buying and Selling by Quarter for Forward Pharma A/S (NASDAQ:FWP)

Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.